newsfilter
← Latest News
Business Wire·

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

CYDYNTRA
  • Natera Inc. and CytoDyn Inc. announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics & generate real-world molecular insights for CytoDyn's metastatic colorectal cancer (mCRC) program.
  • Natera will assess clinical trial samples from CytoDyn's completed CLOVER Phase 2 study (NCT06699836) using its Signatera™ assay to monitor molecular response patterns associated with leronlimab treatment.
  • Natera will provide customized real-world data analyses leveraging its proprietary oncology database containing over 2 million plasma timepoints & enriched clinical records.
  • The multimodal dataset integrates molecular response data with electronic medical records to analyze patient populations, treatment patterns, & ctDNA response rates across diverse clinical settings.
  • Insights from the collaboration aim to inform future leronlimab development strategies, including clinical trial design, biomarker-driven patient selection, & translational research.
  • The CLOVER study evaluates leronlimab combined with trifluridine/tipiracil & bevacizumab in patients with previously treated mCRC.
  • CytoDyn CEO Jacob Lalezari stated the partnership will provide valuable insights into ctDNA response kinetics to guide future development for leronlimab in colorectal cancer & other solid tumors.
  • Natera VP Matt Love noted the platform enables biopharma partners to better understand disease biology, treatment response, & patient outcomes to inform development decisions.